FIA
ADMS

FNY Investment Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

FNY Investment Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,500
Closed -$130K – 1146
2018
Q3 		$130K Buy
6,500
+1,438
+28% +$33.8K 0.03% 241
2018
Q2 		$130K Buy
+5,062
New +$140K 0.05% 195

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

FNY Investment Advisers's ADMS Position: Q4 2018 in Review

FNY Investment Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 6,500 shares — an estimated $130K sold.

FNY Investment Advisers first reported a position in ADMS in Q2 2018 and held it in 2 quarters. The position peaked at $130K in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • FNY Investment Advisers reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 6,500 Adamas Pharmaceuticals shares in Q4 2018, an estimated $130K.
  • FNY Investment Advisers first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Adamas Pharmaceuticals position peaked at $130K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.